Epigallocatechin-3-Gallate Suppresses the Expression of TNF-α-Induced MMP-1 via MAPK/ERK Signaling Pathways in Human Dermal Fibroblasts

  • Won Hea-Ryeoun
    School of Cosmetic Science and Beauty Biotechnology, Semyung University
  • Lee Pyeongjae
    School of Industrial Bio-pharmaceutical Science, Semyung University
  • Oh Sol-ra
    School of Cosmetic Science and Beauty Biotechnology, Semyung University
  • Kim Yong-Min
    School of Cosmetic Science and Beauty Biotechnology, Semyung University

書誌事項

タイトル別名
  • Epigallocatechin-3-Gallate Suppresses the Expression of TNF-α-Induced MMP-1 <i>via</i> MAPK/ERK Signaling Pathways in Human Dermal Fibroblasts

この論文をさがす

抄録

<p>Deeper wrinkles and loss of elasticity are one of the skin-aging symptoms. Collagen breakdown by matrix metalloproteinase-1 (MMP-1), which is induced by reactive oxygen species (ROS) and pro-inflammatory cytokines, has been known to be responsible for these skin-aging symptoms. Therefore, much attention has been paid to chemicals to suppress the MMP-1 activity. Epigallocatechin-3-gallate (EGCG), catechin rich in green tea, has been reported to show antioxidant and protect skin from various stimuli such as UV and chemicals. In this study, we evaluated the inhibitory effect of EGCG on MMP-1 gene expression and secretion in tumor necrosis factor-α (TNF-α)-treated human dermal fibroblast cells (Hs68 cells). Pre-treatment with EGCG (10 and 20 µM) suppressed TNF-α-induced MMP-1 expression and secretion. EGCG also reduced the phosphorylation of extracellular signal regulated kinase (ERK) significantly but not that of p38 activation and c-Jun N-terminal kinase (JNK). Besides, EGCG (10 and 20 µM) showed the inhibitory effect on mitogen-activated protein extracellular kinase (MEK) and Src phosphorylation which is reported to be upstream signal proteins of ERK signal pathway. Based on these results, EGCG might have potential activity to slow down the skin-aging through inhibition of collagen breakdown, which remains to be elucidated.</p>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (25)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ